iSpecimen Inc.
ISPC
Positions held
Your positionsISPC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $2.75M | Enterprise value | -$1.43M | Trailing P/E | — | Forward P/E | -1.38 |
| PEG | — | Price / book | 0.96 | Beta | 1.65 | Dividend yield | 0.00% |
| Revenue growth | -78.7% | Earnings growth | — | Gross margin | -108.3% | Operating margin | -9.0% |
| Profit margin | 0.0% | ROE | -9.7% | ROA | -87.7% | Debt / equity | 0.14 |
| Current ratio | 0.82 | Free cash flow | -$5.58M | Analyst recommendation | none | Mean target | — |
| 52w high | $37.60 | 52w low | $1.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | $0.2M | $0.1M | $0.1M | $0.7M | — |
| Op margin | -897.1% | -1627.1% | -5192.9% | -2655.2% | -255.4% | — |
| Net income | -$1.4M | -$2.3M | -$5.0M | -$2.8M | -$1.0M | — |
| Gross margin | 45.2% | 45.9% | -1056.9% | -91.9% | 37.7% | — |
| Gross profit | $0.1M | $0.1M | -$0.5M | -$0.1M | $0.3M | — |
| Operating income | -$1.4M | -$2.5M | -$2.7M | -$2.8M | -$1.8M | — |
- Revenue -3% vs prior quarter ($0.2M vs $0.2M).
- Gross margin 45.2% (was 45.9% prior quarter).
- Operating margin expanded to -897%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.9M | $9.3M | $9.9M | $10.4M | — |
| Op margin | -465.4% | -137.0% | -112.5% | -97.9% | — |
| Net income | -$10.5M | -$12.5M | -$11.1M | -$10.2M | — |
| Gross margin | 1.2% | 42.9% | 51.4% | 54.3% | — |
| Gross profit | $0.0M | $4.0M | $5.1M | $5.6M | — |
| Operating income | -$9.0M | -$12.7M | -$11.2M | -$10.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · iSpecimen Supports Hospital Validation of New Chemistry Analyzer
2026-08-20 · iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
2026-08-20 · iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
2026-08-07 · iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-08-07 · E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
2026-08-07 · E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
2026-08-06 · iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
Price (daily)
Full chart · RSI · MACD · patterns